A collaborative enterprise for multi-stakeholder participation in the advancement of quantitative imaging - PubMed (original) (raw)
. 2011 Mar;258(3):906-14.
doi: 10.1148/radiol.10100799.
Collaborators, Affiliations
- PMID: 21339352
- DOI: 10.1148/radiol.10100799
A collaborative enterprise for multi-stakeholder participation in the advancement of quantitative imaging
Andrew J Buckler et al. Radiology. 2011 Mar.
Abstract
Medical imaging has seen substantial and rapid technical advances during the past decade, including advances in image acquisition devices, processing and analysis software, and agents to enhance specificity. Traditionally, medical imaging has defined anatomy, but increasingly newer, more advanced, imaging technologies provide biochemical and physiologic information based on both static and dynamic modalities. These advanced technologies are important not only for detecting disease but for characterizing and assessing change of disease with time or therapy. Because of the rapidity of these advances, research to determine the utility of quantitative imaging in either clinical research or clinical practice has not had time to mature. Methods to appropriately develop, assess, regulate, and reimburse must be established for these advanced technologies. Efficient and methodical processes that meet the needs of stakeholders in the biomedical research community, therapeutics developers, and health care delivery enterprises will ultimately benefit individual patients. To help address this, the authors formed a collaborative program-the Quantitative Imaging Biomarker Alliance. This program draws from the very successful precedent set by the Integrating the Healthcare Enterprise effort but is adapted to the needs of imaging science. Strategic guidance supporting the development, qualification, and deployment of quantitative imaging biomarkers will lead to improved standardization of imaging tests, proof of imaging test performance, and greater use of imaging to predict the biologic behavior of tissue and monitor therapy response. These, in turn, confer value to corporate stakeholders, providing incentives to bring new and innovative products to market.
© RSNA, 2011.
Similar articles
- Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
Hafner J. Hafner J. J Phys Condens Matter. 2008 Feb 13;20(6):060301. doi: 10.1088/0953-8984/20/06/060301. Epub 2008 Jan 24. J Phys Condens Matter. 2008. PMID: 21693862 - Open Source software and social networks: disruptive alternatives for medical imaging.
Ratib O, Rosset A, Heuberger J. Ratib O, et al. Eur J Radiol. 2011 May;78(2):259-65. doi: 10.1016/j.ejrad.2010.05.004. Epub 2011 Mar 27. Eur J Radiol. 2011. PMID: 21444166 - Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R, Aksu B, Cuine A, Danhof M, Takac MJ, Linden HH, Link A, Muchitsch EM, Wilson CG, Ohrngren P, Dencker L. Gaspar R, et al. Eur J Pharm Sci. 2012 Dec 18;47(5):979-87. doi: 10.1016/j.ejps.2012.09.020. Epub 2012 Oct 6. Eur J Pharm Sci. 2012. PMID: 23046836 - [Development of antituberculous drugs: current status and future prospects].
Tomioka H, Namba K. Tomioka H, et al. Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese. - Future perspectives for intraoperative MRI.
Jolesz FA. Jolesz FA. Neurosurg Clin N Am. 2005 Jan;16(1):201-13. doi: 10.1016/j.nec.2004.07.011. Neurosurg Clin N Am. 2005. PMID: 15561539 Review.
Cited by
- Nuclear medicine radiomics in digestive system tumors: Concept, applications, challenges, and future perspectives.
Huang W, Tao Z, Younis MH, Cai W, Kang L. Huang W, et al. View (Beijing). 2023 Dec;4(6):20230032. doi: 10.1002/VIW.20230032. Epub 2023 Jul 28. View (Beijing). 2023. PMID: 38179181 Free PMC article. - Review of the use of radiomics to assess the risk of recurrence in early-stage non-small cell lung cancer.
Libling WA, Korn R, Weiss GJ. Libling WA, et al. Transl Lung Cancer Res. 2023 Jul 31;12(7):1575-1589. doi: 10.21037/tlcr-23-5. Epub 2023 Jul 18. Transl Lung Cancer Res. 2023. PMID: 37577298 Free PMC article. Review. - Predictive value of 18F-FDG PET/CT multi-metabolic parameters and tumor metabolic heterogeneity in the prognosis of gastric cancer.
Wang J, Yu X, Shi A, Xie L, Huang L, Su Y, Zha J, Liu J. Wang J, et al. J Cancer Res Clin Oncol. 2023 Nov;149(16):14535-14547. doi: 10.1007/s00432-023-05246-4. Epub 2023 Aug 12. J Cancer Res Clin Oncol. 2023. PMID: 37567986 - Repeatability of radiomics studies in colorectal cancer: a systematic review.
Liu Y, Wei X, Feng X, Liu Y, Feng G, Du Y. Liu Y, et al. BMC Gastroenterol. 2023 Apr 14;23(1):125. doi: 10.1186/s12876-023-02743-1. BMC Gastroenterol. 2023. PMID: 37059990 Free PMC article. - Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians.
Zhou H, Luo Q, Wu W, Li N, Yang C, Zou L. Zhou H, et al. Front Immunol. 2023 Mar 1;14:1088874. doi: 10.3389/fimmu.2023.1088874. eCollection 2023. Front Immunol. 2023. PMID: 36936913 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous